SciRhom
Key Facts
Invested since | 2016 |
Based in | Bavaria |
About the company
SciRhom GmbH is a therapeutic antibody company developing first-in-class antibodies against iRhom2, a key modulator of several major pro-inflammatory signaling pathways, including TNF-alpha signaling. Based on a decade of cutting-edge bench research and the completion of a challenging, yet ultimately successful antibody campaign, SciRhom is now in the unique position to pursue the development of monoclonal antibodies against iRhom2 for the treatment of major autoimmune diseases.
Do you want to
know more about this company?
SciRhom in the news

Against the tide – HTGF portfolio SciRhom company rewarded for courage with EUR 63 million Series A financing
